| Metric | Value (₹ Cr) | vs Q1 FY27 |
|---|---|---|
| Revenue | 661.42 | 26.9% |
| Total Income | 669.24 | 27.0% |
| Expenditure | 599.36 | 26.9% |
| PBT | 69.88 | 28.1% |
| Net Profit | 53.06 | 32.1% |
| OPM | 12.77% | 0.82pp |
| NPM | 7.93% | 0.30pp |
| EPS | 2.03 | 23.0% |
30% growth, but margins refuse to budge—the capacity ceiling explains why
Lumino delivered a textbook 30% YoY revenue beat (₹661 Cr) with order book now at ₹3,400 Cr. The catch: existing capacity at 80% utilization leaves no room to run, and despite a product mix shift toward premium HTLS and AL-59 conductors, management held EBITDA guidance at 12–13%. The call reveals why—and whether new facility ramps can unlock margin expansion.
₹661.4 Cr
+30% YoY vs. ₹509 Cr
₹1,183 Cr
+25% YoY, EBITDA 13.1%
12.8%
flat vs. Q2 FY26
₹53.1 Cr
+32% QoQ, 7.9% margin
₹3,400 Cr
₹2.2k Cr mfg (5–6m), ₹1.2k Cr EPC (3y)
80%
40k MT existing at near ceiling
On the surface, Lumino's Q2 reads like a home run: 30% revenue growth, strong order inflows (₹3,400 Cr backlog, up ₹515 Cr in October alone), and successful listing (₹500 Cr IPO, ₹337 Cr debt repaid). But lift the hood and the tension appears: margins are flat despite a deliberate shift into premium product categories—HTLS (high-temperature low-sag) conductors and AL-59 aluminum alloy cables, each commanding 1.5× conventional pricing. The company's existing 40k MT capacity is now at 80% utilization. When analysts pressed management on EBITDA expansion as new products scale, management held firm at guidance of 12–13% for manufacturing. That steadfast refusal to raise is the real story of the quarter: growth is real and order-backed, but the margin proof points are still ahead.
Revenue growth confirmed, margin quality under test
The ₹661.4 Cr revenue in Q2 checks out precisely: versus ₹509 Cr in Q2 FY26, that's a clean 30% YoY advance. Year-to-date (H1 FY27 ₹1,183 Cr) shows 25% YoY growth, and the quarterly progression from Q1 to Q2 accelerated (+27% QoQ revenue, +32% QoQ PAT). The delivery matches the call. Manufacturing represented ₹831 Cr of H1 revenue (65% conductors, 35% cables), and the EPC segment added ₹352 Cr. Profitability also landed on target: EBITDA of ₹84.6 Cr (~12.8% margin) and PAT of ₹53.1 Cr (7.9% margin) align with filed results.
Where the story tightens is on margin trajectory. EBITDA margin in Q2 FY27 was 12.8%, the same as Q2 FY26. The company shifted ~₹50 Cr in H1 revenue (4% of manufacturing) into the nascent HTLS conductor segment—a product with premium positioning and, by management's own description, "slightly better" EBITDA than conventional conductors. Yet blended manufacturing EBITDA came in at 13% in H1 (flat vs. H1 FY26). This is the gap: if new products are truly premium, why aren't blended margins expanding? Management's answer: competitive entry in AL-59 is pressuring conventional conductor volumes, so the conventional product is eroding. The new products' margin gains are offset by mix headwinds in the base business. No net uplift—yet.
Order book and capacity: the constraint made visible
The order book expansion to ₹3,400 Cr is genuine and diversified. Manufacturing orders (₹2,200 Cr, or ~65% of backlog) carry a 5–6 month execution TAT, implying roughly ₹367–440 Cr in quarterly revenue run-rate if executed smoothly. EPC orders (₹1,200 Cr, or ~35%) stretch across 3 years, with payment terms of 60% supply, 30% erection, 10% retention—a model that ties working capital. October 2026 alone added ₹386 Cr (Green Corridor Phase 3 transmission line orders), plus ₹555 Cr in L1 tenders. The pipeline is real.
But here is the hard limit: the existing Howrah facility operates at 40,000 metric tons per annum capacity, and as of H1 FY27, it is at roughly 80% effective utilization (down from 82–83% in FY26, due to a mix shift toward higher-value products that occupy the same throughput). Management flagged this bluntly: "from the existing plant, hardly there would be any major growth coming up in terms of quantity." The company has ~8,000 MT of slack on a 40k MT base. Unless order velocity slows sharply, that slack fills within weeks. Q2 delivered ₹661 Cr on ~13,800 MT volumes (a slight volume dip YoY due to mix, but similar throughput). The math is tight: to grow revenue materially in H2 FY27 without the new facility, Lumino would need average selling price (ASP) inflation or a drop in order intake—neither of which is visible in guidance or market signals.
The Ranibat facility: when it arrives, how much it changes
Lumino's escape valve is the Ranibat facility, a greenfield addition. Phase 1 (10,000 MT capacity) is slated to begin production in December 2026 or January 2027, roughly 6–7 weeks from the call. Phase 2 (another 25,000 MT) is planned for phased rollout through September 2027 and beyond, targeting a combined 75,000 MT capacity at 80%+ utilization by FY28–29. If Phase 1 ramps on schedule, H2 FY27 should see incremental production—perhaps 2,000–3,000 MT at low utilization—providing modest revenue upside but not a dramatic acceleration. The real inflection comes in FY28: if Ranibat reaches 20,000+ MT by mid-year and maintains blended EBITDA at 12–13%, then H2 FY28 revenues could push toward ₹800–900 Cr per quarter.
That is forward-looking. For now, the facility exists as a plan, not a producer. Management's confidence in the timeline is backed by in-house design and prior execution experience; however, facility ramps in India historically slip 2–4 weeks, and any slippage compresses H2 FY27 upside.
Q2 FY27 revenue ₹661 Cr, 30% YoY growth
Delivered ₹661.4 Cr; Q2 FY26 baseline ₹509 Cr = 30.0% growth
Supported
EBITDA margin 12.8% maintained despite product mix shift to HTLS/AL-59
H1 blended manufacturing EBITDA 13.0%, flat vs. prior year; new products ~50 bps premium but offset by conventional volume erosion
Supported, but margin expansion not yet evident
HTLS TAM ₹5,000 Cr annually, targeting 10–15% penetration
H1 backlog ₹50 Cr on new product; TAM is forward estimate, unverified vs. external sources
Plausible but unproven at scale
Order book ₹3,400 Cr with 5–6 month mfg TAT, 3-year EPC TAT
Sept 30 base ₹2,885 Cr + Oct additions ₹386 Cr + L1 tenders ₹555 Cr = ₹3,826 Cr stated, per OB bridge
Supported; TAT splits 65% mfg, 35% EPC confirmed
New Ranibat facility adds 35k MT in phases; Phase 1 (10k MT) starts Q4 FY27 production
Capex plan outlined; no capex amount or funding source specified; timing is Dec 2026/Jan 2027 production start
Supported in principle; execution risk typical of facility ramps
EBITDA guidance 12–13% manufacturing, 13–14% EPC; no expansion expected
H1 manufacturing EBITDA 13.0%, EPC 13.5%; guidance is maintenance, not uplift
Supported; implies no margin expansion from mix or new facility in near term
What changed on this call vs. IPO listing (Sept 2026)
Order book expansion clarified. September listing disclosed ₹2,885 Cr order book; October inflows (₹386 Cr Green Corridor + ₹555 Cr L1 tenders) pushed the backlog narrative forward. This is organic growth in the pipeline, not engineering; the market took note of the October velocity.
HTLS and AL-59 strategy articulated post-listing. The IPO prospectus positioned these as growth vectors; the call put numbers on them (₹50 Cr H1 backlog, ₹5k Cr TAM, 10–15% penetration target). Investors now have a concrete track record: demand for HTLS cables exists (BHEL, BPCL, Hatech Power, IIG Infra all placed orders), and early ₹50 Cr backlog validates adoption. However, the 10–15% penetration assumption remains unproven.
Capacity plan moved from vague to phased. IPO filings mentioned capacity expansion; the Q2 call nailed down the timeline (Phase 1 Dec 2026, Phase 2 ongoing, 75k MT target by FY28–29) and gave a production start window. This removed optionality and introduced execution risk.
EBITDA margin guidance held firm despite pushback. Analysts repeatedly asked whether margin expansion should be expected as new products scaled. Management's answer: 12–13% is the sustainable range. New products are premium-priced but market adoption is gradual, conventional volumes are eroding, and competitive entry in AL-59 is real. No concessions. This is a recalibration of expectations—the market was hoping for 50–100 bps margin uplift; management signaled none.
How the street is positioned—and what the price action says
Lumino's stock closed at ₹94.16 on November 9, 2026, trading roughly 22.8% below its all-time high of ₹122 and +10.1% above its 52-week low of ₹85.51. It is trading below its 20-day simple moving average (₹95.30), implying downtrend momentum. RSI of 45.2 indicates neutral positioning (not overbought, not oversold). Volume trends are normal—no institutional stampede in or out.
Bulk and block activity reveals institutional repositioning, not conviction. Since mid-September (around IPO listing), bulk deals show a pattern of small trades by Junomoneta Finsol, Yuga Stocks, and HRTI Private Limited in the ₹104–111 range—roughly ₹10–12 per share below the current level. These are consistent with post-IPO share stabilization and profit-booking by IPO subscribers. Notably, there is no promoter insider activity in the bulk blocks and no significant FII/DII buying spikes visible in the data. The absence of insider conviction buying near the highs (when the stock was at ₹122) is a soft warning: insiders did not chase the run-up.
The 22% drawdown from ATH is not abnormal for a newly-listed infrastructure play in a neutral market, but it does signal that early enthusiasm has faded. The call's refusal to guide higher on margins likely reinforced skepticism. Valuation at ₹94 on ~5–6 month forward earnings visibility (orders ÷ TAT) is not cheap, nor is it expensive—it is fairly valued for a company showing steady execution but no step-change growth until Ranibat ramps mid-FY28.
30% YoY revenue growth, order book expanded to ₹3.4k Cr, pipeline validated
New products (HTLS, AL-59) carry 1.5× premium pricing; early ₹50 Cr backlog validates demand
IPO (₹500 Cr) and debt repayment (₹337 Cr) improve leverage; net debt now ₹75 Cr
EBITDA margin guidance held flat at 12–13% despite product mix shift—no expansion expected near term
Existing 40k MT capacity at 80% utilization; growth limited until Ranibat ramps (Dec 2026 start, Q4 FY27 production)
EPC 3-year TAT orders introduce execution risk and working capital drag; government utility payment delays common (₹140 Cr WBEB collected but timing delayed)
Stock down 22% from ATH; no major insider buying near highs; bulk trades suggest IPO profit-booking
HTLS TAM (₹5k Cr) and penetration rate (10–15%) are management estimates, not market-validated; scale risk remains
Capacity constraint; Ranibat ramp delays into H2 FY27
HighCurrent 40k MT at 80% utilization leaves <8k MT slack. Q4 FY27 production start is Dec 2026/Jan 2027 estimate; any 4–6 week slip erodes H2 FY27 incremental revenue and delays margin inflection to FY28. Facility ramps in India historically slip; this is not engineered risk, it is execution risk.
Margin guidance holds at 12–13% despite new product mix shift
HighHTLS and AL-59 are positioned as premium-margin products, yet management explicitly held EBITDA guidance flat. This signals either (a) competitive intensity in new products is higher than expected, or (b) conventional volume erosion offsets new product gains. Margin inflection proof is deferred; without it, the bull case weakens. FY28 will be the test year.
HTLS TAM penetration rate (10–15%) is unproven
Medium₹5k Cr TAM is a management estimate backed by no third-party data; 10–15% penetration (₹500–750 Cr addressable) is forward guidance. Early ₹50 Cr H1 backlog (1% of addressable) validates demand but not scale. If market adoption is slower or competitive entry erodes pricing, HTLS becomes a niche product, not a growth driver.
EPC working capital and project execution delays
Medium₹1.2k Cr of backlog (35% of total) is EPC with 3-year TAT and 60% supply / 30% erection / 10% retention payment terms. Working capital cycle improved to 111 days but remains elevated vs. manufacturing (46 days). Any project milestone delay or government utility payment slowdown (precedent: ₹140 Cr WBEB collection took time) cascades through cash flow. H2 FY27 is heavily weighted to EPC milestone timing; execution risk is real.
Valuation offers limited margin of safety if capex/margin thesis delays
MediumStock at ₹94 reflects ~5–6 month forward order visibility (₹550–650 Cr quarterly mfg TAT ÷ run-rate P/E on ₹661 Cr Q2 = ~11–13x trailing earnings). If Ranibat slips or margins hold at 12% and don't expand, the stock offers no downside cushion. Drawdown from ₹122 ATH is 22%; further compression to ₹80–85 is possible if execution disappoints.
1 · Ranibat facility production start (December 2026 target)
The Q4 FY27 inflection hinge on this date. Any delay >2 weeks erodes H2 FY27 upside and signals execution risk. Watch for manufacturing capacity utilization beyond 80% in Q3 FY27 (would imply new facility pre-production activity). Production ramp to 5k+ MT in January 2027 would validate timeline.
2 · HTLS backlog velocity and ASP realization
H1 saw ₹50 Cr HTLS revenue. If H2 accelerates to ₹80–100 Cr (implying new orders beyond the current backlog), that signals market adoption. Watch for ASP hold near 1.5× premium; any erosion toward 1.2–1.3x would suggest competitive commoditization. EBITDA margin on HTLS orders should be monitored separately (management claims "slightly better" than conventional; Q3 segment data will clarify).
3 · EPC project milestone realization and working capital conversion
Q2 saw ₹352 Cr EPC revenue on a 3-year TAT backlog; H2 revenue will depend on milestone timing (60% supply, 30% erection). Watch for OCF conversion in H2: if PAT grows but OCF lags, it signals project payment delays (West Bengal precedent). Operating cash flow should track >60% of PAT; anything <50% is a red flag for utility payment stress.
Lumino's Q2 is a clean quarter: 30% revenue growth is real, order book is robust and order-backed, and the company has demonstrated operational discipline through listing and debt reduction. This is steady execution. It is not a step-change. The tension that defines the quarter is unflinching: margins are flat despite a deliberate shift into premium products, and the company's capacity is now at the wall. Management's refusal to raise EBITDA guidance despite the product mix tilt is the honest recalibration of expectations—margin expansion is deferred, not absent. The Ranibat facility is the next chapter; if it ramps on schedule (December 2026 start), and HTLS orders accelerate in H2, then FY28 becomes an inflection year. Until then, Lumino is a "show-me-the-capex" story.
The stock's 22% drawdown from ATH reflects this patience: the market is waiting for proof, not guessing. At ₹94, the risk-reward is fair but not compelling; the single number to track from here is manufacturing utilization in Q3 FY27 (watch for signs of capacity tightening or new facility pre-production). If utilization stays at 80–82% through October–November, Ranibat timing is on track. If it falls below 75%, that would signal demand softening or mix deflation—a yellow flag for the bull case.
Strong Q2 growth, capacity constraints limit near-term momentum
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
First earnings call post-listing (Sept 2026). Delivered results match stated Q2 figures exactly. No prior guidance to measure against.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 30% YoY growth and order book (₹3.4k Cr) validate execution. However, existing 40k MT capacity now at 80% utilization limits near-term momentum until new 35k MT facility ramps (Q4 FY27/Q1 FY28). EBITDA margin guidance of 12-13% shows no expansion, with new product categories (HTLS, AL-59) facing margin headwinds despite premium pricing. Growth is order-constrained, not demand-constrained.
₹661.4 Cr
Revenue · +30% YoY₹53.1 Cr
Reported PAT · +null% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 FY27 revenue ₹661 Cr, 30% YoY vs ₹509 Cr
METDelivered ₹661.4 Cr; Q2 FY26 baseline ₹509 Cr = 30% growth match
Q2 EBITDA ₹84 Cr at 12.8% margin
METDelivered revenue ₹661.4 Cr × 12.8% OPM = ₹84.6 Cr approx
PAT ₹53 Cr at 7.9% margin
METDelivered PAT ₹53.1 Cr, margin 7.9%
H1 FY27 revenue ₹1,183 Cr, 25% YoY growth
METQ2 ₹661.4 Cr + H1 total ₹1,183 Cr implies H1 FY26 ~₹946 Cr; 25% growth holds
Manufacturing revenue H1: ₹831 Cr, 65% from conductors
METCFO stated ₹831 Cr H1, 65% conductor / 35% cables; this is segment mix data
New facility adds 35k MT capacity; current 40k MT at 82-83% FY26 utilization
METStated capacity expansion Ranibat facility from 40k to 75k MT in phases; H1 FY27 utilization ~60-62% effective 80%
HTLS TAM INR5,000 Cr, expecting 10-15% conversion
UnverifiedNo external TAM verification available; management's forward-looking estimate
Going forward, product 70%, EPC 30% revenue split
OVERSTATEDCurrently manufacturing 70% of total, which includes EPC; EPC as standalone is 30%. Split target for H2 is 70/30
Earnings quality
What changed since the last call
Order book expanded to ₹3,400 Cr
UpgradeFrom ₹2,885 Cr (Sept 30) to ₹3,400 Cr (with Oct additions ₹386 Cr + L1 tenders ₹555 Cr), representing 5-6 month manufacturing and 3-year EPC TAT visibility
Capacity plan clarified: 40k → 75k MT by FY28-29
UpgradeNew facility Ranibat adds 35k MT in phases (10k Q4 FY27, ongoing build-out); targets 75k MT capacity at 80%+ utilization by FY28-29
HTLS conductor TAM and strategy stated
NewINR5,000 Cr annual TAM identified, expecting 10-15% conversion; already has ₹50 Cr backlog for 11 kV and 33 kV cables; premium pricing 1.5x vs conventional but market adoption gradual (pending market shift from conventional conductors)
EPC margin guidance reasserted at 13-14%
NeutralNo expansion from historical; management confirmed long-term EPC exposure maintained ~30%, with focus on product company positioning (70% mfg) going forward
The Q&A
Analysts pressed on EBITDA margin expansion post-new facility, product mix shift, and order book realism. Management held firm on 12-13% manufacturing guidance (new products offset high-temp HT cables gains), acknowledged market competition in AL-59, and reframed as product-company strategy rather than EPC growth play. No major concessions or guidance cuts.
Revenue breakdown, cables vs conductors — Ajit Sethi, Eiko Quantum
AnsweredH1 manufacturing ₹831 Cr: 65% conductors, 35% cables. HTLS segment ₹50 Cr H1. New facility focuses on medium/high voltage cables (1.1-33 kV).
EBITDA margin trajectory with new facility — Ajit Sethi, Eiko Quantum
PartialManufacturing EBITDA 12-13%, 13.5% for new high-temp products; blended 12% to 13.5%. New facility Q4 ramp, margins improve gradually once AL-59 penetration rises; expects 12-13% range maintained.
Volume and utilization growth — Ajit Sethi, Eiko Quantum
AnsweredH1 FY27: 13,781 MT vs H1 FY26 ~13,800 MT (slight decrease due to value-added product mix shift). Growth post-Ranibat facility comes online; new facility will add 56,000-60,000 MT annually by year 3.
Trade receivables and working capital — Retail shareholder, [unaudible 00:26:54]
AnsweredWest Bengal Electricity Board: ₹140 Cr total outstanding, ₹138 Cr received; remaining ₹2 Cr only outstanding. Debtors >6m: ₹230 Cr as of March, now ₹215 Cr realized; working capital cycle improved EPC from 120 to 111 days, manufacturing 50 to 46 days.
Order book quality and TAT — Abhishek Kamdar, Value Plus Advisors
AnsweredManufacturing TAT 5-6 months, EPC 3 years. Order book split ~65% mfg (₹2,200 Cr), ~35% EPC (approx 40% of which is spread over 3 years). Focus on cash flow and on-time delivery; order book is executable but not near-term revenue guarantee.
AL-59 pricing and margins — Abhishek Kamdar, Value Plus Advisors
PartialAL-59 premium ~1.5x conventional, but market moving gradually from conventional. EBITDA margin AL-59 slightly better than conventional due to capacity utilization; at 75k MT (80-85% utilization), expect ~56,000-60,000 MT annually with 25,000-35,000 MT in cables, 35,000-40,000 MT conductors split.
HTLS conductor market outlook — Viraj Jain, Individual Investor
AnsweredHTLS TAM INR5,000 Cr annually; expecting 10-15% conversion. Orders received from IIG Infra, Hatech Power, BHEL, BPCL for 11-33 kV cables (~₹50 Cr backlog). Gujarat Electricity Board also ordered INR75 Cr (EPC) including underground cabling (~60% HT cable component).
H2 growth drivers — Garvita Jain, Seven Islands PMS
AnsweredProduct growth expected 30-35% H1 to H2. Product 70%, EPC 30% revenue target. EPC-driven H2 growth unlikely to stress working capital; 80% utilization on new facility will support revenue without capex stress. Cash generation sufficient.
Finance cost and debt trajectory — Garvita Jain, Seven Islands PMS
AnsweredRaised ₹500 Cr, repaid ₹337 Cr debt as of Sept. Remaining debt ₹75 Cr pending (due Nov 15). Finance cost improvement expected ₹15-16 Cr in H2 FY27, ₹20-25 Cr reduction possible in FY28. Debt now at lower level post-IPO.
Labor shortages and execution risks — Viraj Jain, Individual Investor
AnsweredLabor shortages in transmission line projects; Lumino mostly EHV substation work (gang labor model), not severely impacted. Transmission line projects face labor constraints; Lumino's EPC portfolio focused on substations, less exposed to transmission labor gaps.
Guidance
Order book 5-6 month mfg, 3-year EPC TAT
High₹3,400 Cr backlog at Sept 30; split ~65% mfg (₹2,200 Cr), 35% EPC (₹1,200 Cr). Mfg TAT implies quarterly run-rate ~₹550-650 Cr if fully executed.
H2 product revenue growth 30-35% vs H1
MediumNew facility ramp (starting Dec 2026) to drive H2 uplift. Dependent on successful production ramp and order execution. Current capacity constraint (80% utilized) limits upside until new facility comes online.
HTLS TAM ₹5,000 Cr, targeting 10-15% annual penetration
LowTAM is management estimate; 10-15% penetration is forward guidance not yet proven. Early orders ₹50 Cr validate demand but market is nascent.
Manufacturing EBITDA 12-13%, blended with new products 12-13.5%
HighConsistent with H1 actuals (13%). New high-temp HT products add 1-2% premium but demand competitive intensity in AL-59; net margin hold at 12-13%.
EPC EBITDA 13-14%
MediumH1 actual 13.5%; guidance suggests slight compression. EPC project execution dependent on on-time delivery and working capital management.
New Ranibat facility capex to add 35k MT in phases; 10k MT Q4 FY27, ongoing build to 75k MT by FY28-29
MediumPhase 1 (10k MT) starts production Dec 2026/Jan 2027. Phase 2 (25k MT) timeline not specified; targets 80%+ utilization at 75k MT capacity.
Risks the call surfaced
Order execution
MediumEPC order book 3-year TAT spread; any project delay cascades to full-year execution. Working capital tied up until project completion.
New facility ramp
MediumRanibat facility production starts Dec 2026/Jan 2027. Any delay erodes H2 FY27 and FY28 growth assumptions. New product categories (HTLS, AL-59, medium-voltage cables) unproven at scale.
Margin compression
MediumAL-59 and HTLS are nascent segments facing market competition. Management acknowledges premium not substantial (1.5x for AL-59). Conventional conductor demand shrinking as market shifts to AL-59.
Capacity constraint
LowCurrent 40k MT at 80% utilization nearly maxed. Until Ranibat ramps H2/Q4 FY27, revenue growth limited. Order book mostly executable but constrained by mfg capacity.
Working capital stress
LowEPC payment terms: 60% supply, 30% erection, 10% retention; creates significant WC drag. West Bengal board had ₹140 Cr outstanding (now collected); similar delays possible with other government utilities.
Management
Score 7/10. Clear articulation of business model, markets, and strategy. Transparent on challenges (labor, market competition, working capital management). Well-prepared with detailed segment data (revenue split, TAT, margins). Some hedging on margin expansion despite higher-value products. Delivered Q2 results matching stated figures. Order book expanded organically (₹386 Cr in October). Raised ₹500 Cr IPO and repaid ₹337 Cr debt on schedule. New facility project on track (Dec 2026/Jan start). Working capital cycle improved.
1 · Q4 FY27 (Dec 2026)
New Ranibat facility production ramp (Phase 1: 10k MT, Dec 2026/Jan 2027 start)
2 · FY28 (Mar 2027)
Eligibility to bid 765 kV substation tenders post 6 substations completion by March '27
3 · H2 FY27
HTLS cable commercial production (medium voltage 1.1-33 kV range orders ₹50 Cr backlog)
Growth is order-constrained, not demand-constrained.